LORRAINE RUSCH, PH.D.
Dr. Rusch is a highly experienced drug development scientist and executive, specializing in early clinical research and development services. She has significant drug development expertise from the biotechnology industry and is a leader in the contract research organization sector, known for expanding research capabilities and creating unique service offerings to the biopharma industry.
Dr. Fein received her Doctor of Medicine at the University of Witwatersrand Medical School in Johannesburg, South Africa before completing her Residency in Miami, Florida. She is board certified in Family Medicine, is a Certified Physician Investigator and holds medical licenses in both North Carolina and Florida.
VP OF CLINICAL PHARMACOLOGY SERVICES
Clayton Dehn is a clinical research physiologist with particular expertise in endocrine disorders, especially those related to fertility and metabolic disturbances. Clay brings over 15 years of knowledge and experience as a clinical research professional in the pharmaceutical, device, and CRO industries.
EXECUTIVE VP OF CORPORATE DEVELOPMENT
Doug Copeland is a business executive with extensive experience in a range of businesses in health care and non-healthcare fields. He has served as vice president of a hospital system and in a leadership role in a number of other businesses and organizations.
Our Founder and CEO, Dr. Adnan Mjalli, is an internationally recognized entrepreneur in the business of drug discovery and development of new medicines. He is the founder of High Point Pharmaceuticals and TransTech Pharma (now vTv Therapeutics), High Point Clinical Trials Center and PharmaCore (now Cambrex). Dr. Mjalli served as Chairman and CEO of TransTech Pharma from December 1998-April 2014 and Chairman of PharmaCore fromDecember 1999 – November 2017.
Dr. Mjalli has raised hundreds of millions of dollars for the companies he founded. He has also structured, negotiated, and concluded over a dozen multibillion dollar deals with major global pharmaceutical companies. His work goes well beyond the drug discovery and development arena as he is the founder of more than 20 other companies in the areas of education, energy, agriculture, construction, trade, finance, entertainment and other sectors. These companies focus on Dr. Mjalli’s core values; science, education, technology and advancing human capital in developing countries.
Dr. Mjalli obtained his Ph.D. in Medicinal Chemistry in 1989 from the University of Exeter, UK. His postdoctoral work was carried out at the University of Rochester, NY. Prior to founding his companies, Dr. Mjalli held various positions of increasing responsibility in research and senior management at several pharmaceutical and biotechnology companies including Merck & Co., Inc. and Ontogen Corporation. He has authored hundreds of scientific papers, four book chapters and is an inventor of more than 700 patents and patent applications.
Dr. Mjalli is a member of the American Chemical Society, the World Economic Forum, a member of the Board of Al-Quds University and Chairman of the Advisory Board of Al-Quds Bards College, a member of the board of the American Task Force on Palestine, an honorary fellow of the Islamic World Academy of Sciences, and an honorary member of the Palestine Academy of Science and Technology. He served on the Board of Directors of SIGA Technologies, the North Carolina Biotechnology Center, the Guilford Technology Community College Board, the High Point Economic Development Corporation, the High Point University Board, The Foundation Board of GTCC, the High Point Chamber of Commerce, the Arab American University, and the America-Mideast Educational and Training Service (AMIDEAST).
He is also a frequent speaker, panelist and presenter in international forums on scientific and socio-economic topics.